Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01374685 · ClinicalTrials.gov registry record

Family Communication of Hereditary Breast and Ovarian Cancer Risk Among African Americans

A clinical trial, sponsored by National Human Genome Research Institute (NHGRI).

Terminated
Registry status
8
Enrollment target

NCT01374685: Clinical Trial study, sponsored by National Human Genome Research Institute (NHGRI).

NCT01374685 is a clinical trial that was terminated before completion, run by National Human Genome Research Institute (NHGRI). The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01374685 was terminated before completion, sponsored by National Human Genome Research Institute (NHGRI).

TERMINATED
Registry status
8 participants
Enrollment target

Study Summary

Background: \- Certain genetic mutations are linked to higher rates of cancer. It is important for people with these mutations to tell their families about it. This is because others in the family may also be at greater risk for developing these cancers. They can also pass these genes to their own children. But not much is known about how African Americans tell their family members about the results of their genetic testing. The information from this study can be used to improve genetic counseling services. These services will then be more effective in early cancer detection and prevention in the African American community. Objectives: \- To learn more about how African Americans who have tested positive for BRCA1/2 mutations tell their families about their genetic risk. Eligibility: \- African American (or of African descent) women who recently received positive test results for BRCA1/2 mutations. Design: * Participants will be screened with a basic medical history. * They will be asked general questions about their personal and family history. These include questions on marital and health insurance status, education, and income. * Those in the study will have a 45- to 60-minute phone interview. They will answer questions about how they told their family members about their genetic test results. They will also be asked what that experience was like.

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2011-06-07
Est. Completion 2016-01-07

Why NCT01374685 stopped before completion

NCT01374685 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 8 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT01374685 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01374685 about?

NCT01374685 is a clinical study titled "Family Communication of Hereditary Breast and Ovarian Cancer Risk Among African Americans". Background: \- Certain genetic mutations are linked to higher rates of cancer. It is important for people with these mutations to tell their families about it. This is because others in the family may also be at greater risk for developing these cancers. They can also pass these genes to their own ...

What is the current status of trial NCT01374685?

This trial is currently terminated. The enrollment target is 8 participants. The study started on 2011-06-07. Estimated completion is 2016-01-07.

Who is sponsoring clinical trial NCT01374685?

This trial is sponsored by National Human Genome Research Institute (NHGRI), which has 185 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01374685, the US trial registry maintained by the National Library of Medicine. NCT01374685 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.